Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2019 | Telomere length screening

Carlo Dufour • 14 Jun 2019
EHA 2019
Anemias

Carlo Dufour, MD, Gaslini Children’s Hospital, Genoa, Italy, discusses how telomere length screening can be helpful for the diagnosis of cytopenic patients at the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands.

More from Carlo Dufour

Guidelines on the diagnosis and management of neutropenia
1:49
Guidelines on the diagnosis and management of neutropenia
Carlo Dufour • 15 Apr 2024
Distinguishing late-onset neutropenia from classical primary neutropenia
2:55
Distinguishing late-onset neutropenia from classical primary neutropenia
Carlo Dufour • 15 Apr 2024
Immune-mediated bone marrow failure diseases & their pathophysiology: aplastic anemia, LR-MDS & PNH
3:18
Immune-mediated bone marrow failure diseases & their pathophysiology: aplastic anemia, LR-MDS & PNH
Carlo Dufour • 15 Apr 2024
New guidelines for the management of neutropenia & challenges in this space
4:55
New guidelines for the management of neutropenia & challenges in this space
Carlo Dufour • 23 Apr 2023

Related Videos

Managing ruxolitinib-associated anemia in myelofibrosis: dose reduction and add-on therapies
1:48
Managing ruxolitinib-associated anemia in myelofibrosis: dose reduction and add-on therapies
Ciro Rinaldi • 10 Sep 2026
Beyond JAK inhibitors: emerging approaches to anemia management in myelofibrosis
4:29
Beyond JAK inhibitors: emerging approaches to anemia management in myelofibrosis
Prithviraj Bose • 18 Sep 2026
Distinguishing disease- and treatment-related anemia in myelofibrosis
1:42
Distinguishing disease- and treatment-related anemia in myelofibrosis
Aaron Gerds • 21 Sep 2026
Insights into the evolving treatment paradigm for myelofibrosis beyond spleen and symptom control
1:16
Insights into the evolving treatment paradigm for myelofibrosis beyond spleen and symptom control
Haifa Kathrin Al-Ali • 13 Jun 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals